Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study

BACKGROUND: QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β(2)-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium for the treatment of COPD. The QUANTIFY study compared QVA149 with a free-dose bronchodilator...

Descripción completa

Detalles Bibliográficos
Autores principales: Buhl, Roland, Gessner, Christian, Schuermann, Wolfgang, Foerster, Karin, Sieder, Christian, Hiltl, Simone, Korn, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Chronic Obstructive Pulmonary Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392202/
https://www.ncbi.nlm.nih.gov/pubmed/25677679
http://dx.doi.org/10.1136/thoraxjnl-2014-206345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392202/
https://www.ncbi.nlm.nih.gov/pubmed/25677679
http://dx.doi.org/10.1136/thoraxjnl-2014-206345

Ejemplares similares